BR100 Increased By (0.77%)
BR30 Increased By (0.87%)
KSE100 Increased By (0.78%)
KSE30 Increased By (0.83%)
AGHA 6.45 Increased By ▲ 0.07 (1.1%)
BECO 4.37 Increased By ▲ 0.02 (0.46%)
BML 62.83 Increased By ▲ 0.28 (0.45%)
BOP 31.48 Increased By ▲ 0.09 (0.29%)
CNERGY 11.79 Increased By ▲ 0.06 (0.51%)
CSIL 5.82 Decreased By ▼ -0.09 (-1.52%)
FCCL 61.70 Decreased By ▼ -0.01 (-0.02%)
FFL 15.00 Increased By ▲ 0.21 (1.42%)
FNEL 1.30 Increased By ▲ 0.06 (4.84%)
KEL 6.33 Increased By ▲ 0.01 (0.16%)
KOSM 5.80 Decreased By ▼ -0.10 (-1.69%)
LOTCHEM 24.85 Increased By ▲ 0.16 (0.65%)
MLCF 105.85 Increased By ▲ 1.92 (1.85%)
NBP 174.65 Increased By ▲ 1.33 (0.77%)
NCPL 52.15 Increased By ▲ 0.32 (0.62%)
NPL 54.61 Increased By ▲ 0.58 (1.07%)
OGDC 318.49 Increased By ▲ 2.62 (0.83%)
PACE 9.30 Increased By ▲ 0.04 (0.43%)
PAEL 35.81 Increased By ▲ 0.23 (0.65%)
PIBTL 14.19 Increased By ▲ 0.53 (3.88%)
PPL 229.00 Increased By ▲ 2.93 (1.3%)
PRL 81.55 Increased By ▲ 1.27 (1.58%)
PTC 46.92 Increased By ▲ 0.28 (0.6%)
SSGC 23.99 Increased By ▲ 0.17 (0.71%)
TBL 9.26 Increased By ▲ 0.02 (0.22%)
TELE 7.65 Increased By ▲ 0.10 (1.32%)
TPL 24.85 Increased By ▲ 0.31 (1.26%)
TPLP 12.93 Decreased By ▼ -0.06 (-0.46%)
TREET 25.95 Decreased By ▼ -0.03 (-0.12%)
TRG 53.79 Increased By ▲ 0.46 (0.86%)
By

Sanofi’s first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi’s website.

The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.

Currency changes would drag 2024 earnings lower by between 5.5% and 6.5% at current rates, it added.

Finance chief Francois-Xavier Roger told a media call that the decline in the Argentine Peso was a particular drag on first-quarter overseas sales.

Quarterly sales of eczema and asthma drug Dupixent jumped a currency adjusted 25% to 2.84 billion euros, in line with analyst expectations and accounting for 27% of group sales.

CFO Roger, previously at Nestle, said that preparations to list the Consumer Healthcare division on the Paris stock exchange from the fourth quarter were fully on track but other options, such as a sale, were still possible.

Chief Executive Paul Hudson has been trying to regain battered investor confidence in the drug pipeline since he unexpectedly abandoned 2025 margin targets last October under a plan to boost drug development spending.

Analysts have said the recent market debuts of drugs including Beyfortus, to protect infants against a common respiratory infection, are indicative of the company’s medium-term earnings prospects. Quarterly sales of Beyfortus came in at a better than expected 182 million euros.

Comments

Comments are closed for this article.